Bionomics Limited (ASX: BNO) today announced it had identified a...

Bionomics Limited (ASX: BNO) today announced it had identified a safe
dosage for Phase II clinical trials of BNC105, its novel vascular disrupting
agent (VDA) for the treatment of solid tumour types, and that it has contracted
Hoosier Oncology Group Inc. (“HOG”) to conduct a Phase II trial to evaluate
the efficacy of BNC105 in renal cell carcinoma. Bionomics also recently
initiated a Phase I clinical trial for BNC210, its potential blockbuster antianxiety
drug.

ASX ANNOUNCEMENTS

02/07/2009 11:06AM Open Briefing - BNO CEO on Milestones Achieved

02/07/2009 9:22AM BNO - US Clinical Trial of BNC105 in Renal Cell Cancer